Zucara Therapeutics Doses First Subject in Phase 1 Trial of ZT-01 – Phase 1 Trial to Evaluate ZT-01 for the
Zucara Therapeutics Announces US$21 Million Series A Financing
Zucara Therapeutics Announces US$21 Million Series A Financing – Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials
Zucara Therapeutics Presents New Data at European Association for the Study of Diabetes
Dr. Richard Liggins, Chief Scientific Officer, presenting at EASD in Barcelona. TORONTO, Canada and BARCELONA, Spain: Zucara Therapeutics Inc., a
Zucara Therapeutics Secures Grant from GlycoNet to Expand and Validate their Drug Therapy Model for Type 1 Diabetes to Type 2 Diabetes
Toronto & Vancouver, Canada: Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in
Remembering Dr. Mladen Vranic: The Outstanding Diabetes Researcher
(Michael Midmer & Dr. Mladen Vranic) Dr. Mladen Vranic, a leading scientist and advocate for the advancement of diabetes research,
Zucara Therapeutics Adds Additional Drug Development Executives to its Board of Directors
TORONTO, Canada: Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with
Susan Peers Joins Zucara’s Leadership Team
Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with Type 1
Zucara Therapeutics – Helping people with diabetes sleep safely and soundly
Typically occurring overnight, hypoglycemia puts over 8 million people with diabetes at fatal risk during their sleep. Current therapies offer
Zucara Therapeutics Secures US$3.9M from the Helmsley Charitable Trust to Advance Diabetes Drug Candidate to Clinical Trials
Toronto and Vancouver, Canada: Zucara Therapeutics Inc., a diabetes life sciences company advancing the first once-daily therapeutic to prevent low blood
Zucara Therapeutics Receives Funding to Advance Lead Drug Candidate
VANCOUVER and TORONTO, Canada — Zucara Therapeutics Inc., a pre-clinical life sciences company advancing a novel long-term therapeutic approach to